| Zheng Zhang,Peng Tan,Baoguo Mi,Chao Song,Yi Deng,Hanfeng Guan. Therapy for bone metastasis from different cancers. Oncol Transl Med, 2016, 2: 55-60. |
| Therapy for bone metastasis from different cancers |
| Received:February 01, 2016 Revised:March 18, 2016 |
| View Full Text View/Add Comment Download reader |
| KeyWord:bone metastasis; skeletal-related events (SREs); therapy |
| Author Name | Affiliation | E-mail | | Zheng Zhang | Department of Orthopaedic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | zhenren_122@163.com | | Peng Tan | Department of Orthopaedic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | zhenren_122@163.com | | Baoguo Mi | Department of Orthopaedic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | zhenren_122@163.com | | Chao Song | Department of Orthopaedic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | zhenren_122@163.com | | Yi Deng | Department of Orthopaedic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | zhenren_122@163.com | | Hanfeng Guan | Department of Orthopaedic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | hguan@hust.edu |
|
| Hits: 6581 |
| Download times: 7701 |
| Abstract: |
| The bone is the most common target organ of cancer metastasis. Bone metastasis leads to considerable
morbidity due to skeletal-related events (SREs). These include bone pain, hypercalcemia, pathologic fractures,
and compression of the spinal cord. Cancers such as those of the lung, breast, prostate, and kidney
are more likely to cause SREs than other cancer types. Additionally, some blood cancers, including multiple
myeloma and lymphoma, frequently cause SREs. In this article, we review the conventional therapies for
metastatic bone disease, including drug therapy, radiotherapy, and surgery. Among osteoclast-targeting
agents, bisphosphonates and nuclear factor kappa-B ligand inhibitors are the most widely used agents to
prevent cancer-related bone loss. Unsealed radioisotopes are also considered promising in cancer therapy.
Currently, iodine-131, strontium-89, and radium-223 are available for the treatment of bone metastasis.
However, the treatments for blood cancers with SREs are different from those of other cancers. In those
cases, new classes of agents including proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies,
and histone deacetylase inhibitors have shown remarkable efficacy. We also discuss the potential
development of new therapies for these diseases. |
| Close |
|
|
|